# Pinealon — Research Peptide Profile

> Pinealon (Glu-Asp-Arg) is a Khavinson tripeptide studied for neuroprotection: dendritic spine data in Alzheimer's models, DNA binding & evidence limits.

Source: https://peptpedia.org/peptide/pinealon | Published: 2026-09-18 | Last updated: 2026-09-18

Pinealon (Glu-Asp-Arg) is a Khavinson-school tripeptide investigated for neuroprotection. Cell and animal studies report reduced oxidative stress, preserved dendritic spines in Alzheimer's disease models, and improved cognition in rat offspring after prenatal hyperhomocysteinemia. Controlled human trials have not been published.

## Overview

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed within Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the class of ultrashort peptides proposed to regulate gene expression directly rather than through cell-surface receptors, and it is investigated primarily as a neuroprotective agent. Published work shows that pinealon penetrates living cells and accumulates in the nucleus, binds DNA with sequence specificity, limits reactive oxygen species accumulation in neuronal and immune cells, and preserves dendritic spines in cellular and mouse models of Alzheimer's disease. In Russian research practice it is grouped with other peptide neuroprotectors such as Cortexin and [Semax](/peptide/semax). Human evidence is limited to reports from the originating research lineage; no controlled clinical trials in Western peer-reviewed journals have been published.

## Molecular Profile

- **Category:** bioregulators
- **Molecular formula:** C15H26N6O8
- **Molecular weight:** 418.40 g/mol
- **CAS number:** 175175-23-2
- **Amino acid sequence:** Glu-Asp-Arg
- **Also known as:** EDR peptide, Glu-Asp-Arg, EDR tripeptide
- **Half-life:** Not established; no published pharmacokinetic data in any species
- **Solubility:** Soluble in water (formal solubility characterization not published)
- **Storage:** Store lyophilized at -20°C.

## Mechanism of Action

Pinealon's proposed mechanism is epigenetic rather than receptor-mediated. Fluorescein-labeled pinealon was shown to enter HeLa cells and reach the nucleus and nucleolus, and in vitro binding assays demonstrated sequence-specific interaction with DNA, with preferential binding to CAG-containing oligonucleotides and sensitivity to cytosine methylation status. Molecular docking against promoter regions identified computed binding sites in genes relevant to Alzheimer's pathogenesis, including CASP3, NES, GAP43, APOE, SOD2, PPARA, and PPARG. Functionally, pinealon dose-dependently restricted reactive oxygen species accumulation in cerebellar granule cells, neutrophils, and PC12 cells, reduced necrotic cell death, and altered ERK1/2 activation timing and cell-cycle parameters. Molecular modeling also identifies Glu-Asp-Arg as an efficient computed ligand of the LAT1, LAT2, and PEPT1 amino acid and peptide transporters, a proposed route of cellular uptake (PMID: 36979488). These findings support a model in which the tripeptide enters neurons, interacts with genomic DNA or associated proteins, and shifts expression of antioxidant, apoptotic, and plasticity-related genes.

## Key Research Findings

- Pinealon (Glu-Asp-Arg) penetrates living cells and reaches the nucleus, where it binds DNA sequence-specifically, preferring CAG-containing sequences and responding to cytosine methylation status.
- In an in vitro Alzheimer's model, pinealon at 200 ng/ml increased mushroom dendritic spines in hippocampal neurons by 71 percent, returning the parameter to normal levels.
- In 5xFAD Alzheimer's-model mice, pinealon and the related KED peptide prevented dendritic spine loss, with computed binding sites in promoters of CASP3, NES, GAP43, APOE, SOD2, PPARA, and PPARG.
- Pinealon dose-dependently limited reactive oxygen species accumulation and necrotic death in cerebellar granule cells, neutrophils, and PC12 cells, with effects on ERK1/2 signaling and the cell cycle.

## Safety & Tolerability

Pinealon has no published controlled human safety data. The entire evidence base is preclinical cell and animal work plus Russian-language reports of clinical use from the originating research group, so its safety in humans is uncharacterized. Cell and animal studies did not report toxicity at the concentrations used, but efficacy experiments are not safety evaluations.

**Human data status:** No controlled human trials have been published. Human exposure is documented only in Russian-language literature from the originating research lineage, including reports of use in elderly patients, which cannot be evaluated by standard evidence-based medicine criteria.

**Regulatory status:** Not approved by the FDA, EMA, or any other Western regulatory agency; a research compound.

- Cell-culture work found pinealon restricted reactive oxygen species accumulation and reduced necrotic cell death at nanogram concentrations without reported cytotoxicity, but these were efficacy-oriented in vitro experiments, not safety studies. (evidence tier: in-vitro; [PMID 21978084](https://pubmed.ncbi.nlm.nih.gov/21978084/))
- In a prenatal rat model, pinealon administered to methionine-loaded pregnant rats improved offspring cognitive outcomes and reduced neuronal oxidative stress markers; developmental exposure in animals produced no reported harm, but no formal reproductive toxicology program exists. (evidence tier: animal; [PMID 22567179](https://pubmed.ncbi.nlm.nih.gov/22567179/))
- A Russian-language review describes clinical application of pinealon and related peptide neuroprotectors in elderly patients; these are uncontrolled observations from the developing research group rather than monitored safety trials, so the human adverse-effect profile is unknown. (evidence tier: human-observational; [PMID 24738258](https://pubmed.ncbi.nlm.nih.gov/24738258/))

## Dosing Information (Research Context)

No human dosing has been established in peer-reviewed literature. Cell-culture studies used pinealon at nanogram-per-milliliter concentrations (for example, 200 ng/ml in hippocampal neuron cultures), and animal studies administered it parenterally. Dosing protocols circulating in research communities, including microgram-per-day injection schedules, have no basis in published human or animal pharmacokinetic data.

## Researched Effects

- **Dendritic Spine Preservation** (evidence: preliminary): Research demonstrates Pinealon's most specific neuroprotective effect: the preservation of dendritic spines, the synaptic structures lost early in Alzheimer's disease. In primary mouse hippocampal neuron cultures under amyloid synaptotoxicity, pinealon at 200 ng/ml increased the number of mushroom spines by 71 percent and returned the parameter to normal levels. In 5xFAD transgenic Alzheimer's-model mice, pinealon and the related KED peptide prevented dendritic spine loss, and molecular docking linked the effect to computed binding sites in promoters of the CASP3, NES, GAP43, APOE, SOD2, PPARA, and PPARG genes. Because dendritic spine density tracks closely with cognitive function, these findings position pinealon as a research tool for studying synaptic resilience in neurodegeneration, though all data come from a single research lineage.
- **Antioxidant and Cytoprotective Activity** (evidence: preliminary): Cell-culture studies show Pinealon restricts oxidative stress across multiple cell types. In cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells, pinealon dose-dependently limited reactive oxygen species accumulation induced by both receptor-dependent and receptor-independent oxidative stress, while reducing necrotic cell death measured by propidium iodide uptake. The protective effect was accompanied by delayed ERK1/2 activation and cell-cycle modulation, and because the antioxidant effect saturated at lower concentrations than the cell-cycle effects, the authors concluded pinealon can also interact directly with the cell genome. In rat cerebellum neuron cultures the tripeptide promoted activation of antioxidant enzyme synthesis, extending these findings to endogenous defense systems.
- **Cognitive Protection in Animal Models** (evidence: preliminary): Animal research indicates Pinealon protects developing and aging brains under metabolic and environmental stress. In rats with prenatal hyperhomocysteinemia induced by dietary methionine loading, pinealon administration to pregnant dams significantly improved offspring spatial orientation and learning ability, while reducing reactive oxygen species accumulation and necrotic cell numbers in cerebellar neurons isolated from the offspring. In 18-month-old rats exposed to acute hypobaric hypoxia or mild hypothermia, pinealon altered behavioral and neurochemical indices and promoted accumulation of adrenergic mediators and serotonin in brain tissue. These findings support further study of pinealon in models of developmental neurotoxicity, age-related cognitive decline, and stress resilience.
- **DNA Interaction and Gene Expression Modulation** (evidence: preliminary): Mechanistic studies establish Pinealon as a directly genome-interacting peptide. Fluorescein-labeled pinealon penetrated HeLa cells and localized to the cytoplasm, nucleus, and nucleolus, and fluorescence-quenching assays showed it discriminates between nucleotide sequences, binding preferentially to CAG-containing oligonucleotides and recognizing cytosine methylation status. Physical-chemistry work characterized how mono- and divalent ions shape the Glu-Asp-Arg-DNA interaction. This site-specific DNA binding is the proposed basis for epigenetic regulation of gene activity by ultrashort peptides, distinguishing pinealon from neuroprotectants that act through membrane receptors, and it has implications for understanding how very small peptides might influence transcription in aging neurons.
- **Neurochemical Modulation Under Stress** (evidence: preliminary): Comparative animal research examined Pinealon alongside the brain-derived preparation Cortexin in two stress models in aged rats. In 18-month-old animals subjected to acute hypobaric hypoxia, both peptides promoted accumulation of adrenergic mediators in brain tissue, and under mild hypothermia both increased serotonin in the cerebral cortex, changes the authors propose may underlie geroprotective effects. Cortexin showed a more pronounced effect on free-radical processes and caspase-3 activity than pinealon, suggesting overlapping but non-identical pharmacology between complex brain peptide mixtures and single ultrashort peptides. These neurochemical findings have implications for research into stress-axis adaptation, monoamine regulation in aging, and the comparative pharmacology of peptide neuroprotectors.

## Research Applications

- Neuroscience Research
- Alzheimer's Disease Models
- Aging Research
- Oxidative Stress Biology

## Key Studies

### Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease

Khavinson V, Ilina A, Kraskovskaya N, et al. — *Pharmaceuticals (Basel)* (2021) — [PMID 34071923](https://pubmed.ncbi.nlm.nih.gov/34071923/) | [doi:10.3390/ph14060515](https://doi.org/10.3390/ph14060515)

This study tested the EDR (pinealon) and KED tripeptides in the 5xFAD transgenic mouse model of Alzheimer's disease and in an in vitro amyloid synaptotoxicity model. Both peptides prevented dendritic spine loss in 5xFAD mice, and daily intraperitoneal KED at 400 μg/kg from 2 to 4 months of age tended to increase neuroplasticity. Molecular docking of the peptides against double-stranded DNA containing all possible hexanucleotide combinations identified shared low-energy binding sequences, and the EDR peptide was found to have computed binding sites in promoter regions of the CASP3, NES, GAP43, APOE, SOD2, PPARA, PPARG, and GDX1 genes, whose protein products participate in Alzheimer's pathogenesis. The authors propose that the neuroprotective effect operates at the molecular epigenetic level.

### EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease

Khavinson V, Linkova N, Kozhevnikova E, Trofimova S — *Molecules* (2020) — [PMID 33396470](https://pubmed.ncbi.nlm.nih.gov/33396470/) | [doi:10.3390/molecules26010159](https://doi.org/10.3390/molecules26010159)

This review from the developing group synthesizes the molecular evidence for the EDR peptide (Glu-Asp-Arg) in Alzheimer's-relevant biology. It summarizes prior findings that EDR activates gene expression and synthesis of proteins maintaining neuronal functional activity, reduces apoptosis intensity in vitro and in vivo, interferes with dendritic spine elimination in neuronal cultures from Alzheimer's and Huntington's disease model mice, and promotes antioxidant enzyme synthesis in rat cerebellum neuron cultures. The proposed mechanism has EDR entering cells and binding histone proteins and/or nucleic acids, thereby modulating the MAPK/ERK pathway and the synthesis of pro-apoptotic proteins (caspase-3, p53), antioxidant enzymes (SOD2, GPX1), transcription factors PPARA and PPARG, serotonin, and calmodulin.

### Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease

Kraskovskaya NA, Kukanova EO, Lin'kova NS, et al. — *Bulletin of Experimental Biology and Medicine* (2017) — [PMID 28853087](https://pubmed.ncbi.nlm.nih.gov/28853087/) | [doi:10.1007/s10517-017-3847-2](https://doi.org/10.1007/s10517-017-3847-2)

This in vitro study quantified dendritic spine rescue by ultrashort peptides in primary mouse hippocampal neuron cultures exposed to amyloid synaptotoxicity, a cellular model of Alzheimer's disease. Peptide EDR (pinealon) at 200 ng/ml increased the number of mushroom spines by 71 percent and returned this parameter to the normal level, while tripeptide KED at the same concentration increased mushroom spines by 20 percent. Mushroom spines are the mature, stable synaptic contacts most closely tied to memory function. The authors recommend EDR for further experimental study as a candidate neuroprotective agent for Alzheimer's disease prevention and treatment research.

### Pinealon Increases Cell Viability by Suppression of Free Radical Levels and Activating Proliferative Processes

Khavinson V, Ribakova Y, Kulebiakin K, et al. — *Rejuvenation Research* (2011) — [PMID 21978084](https://pubmed.ncbi.nlm.nih.gov/21978084/) | [doi:10.1089/rej.2011.1172](https://doi.org/10.1089/rej.2011.1172)

This cell-biology study tested pinealon (Glu-Asp-Arg) across cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells subjected to oxidative stress from receptor-dependent or receptor-independent triggers. Pinealon dose-dependently restricted reactive oxygen species accumulation and decreased necrotic cell death measured by the propidium iodide test. Protection was accompanied by a delayed time course of ERK1/2 activation and modification of the cell cycle. Because ROS restriction saturated at lower concentrations while cell-cycle modulation continued at higher concentrations, the authors concluded that beyond its antioxidant activity pinealon is able to interact directly with the cell genome.

### Pinealon Protects the Rat Offspring from Prenatal Hyperhomocysteinemia

Arutjunyan A, Kozina L, Stvolinskiy S, et al. — *International Journal of Clinical and Experimental Medicine* (2012) — [PMID 22567179](https://pubmed.ncbi.nlm.nih.gov/22567179/)

This animal study examined whether pinealon protects developing brains from prenatal metabolic stress. Rats were loaded with dietary methionine during pregnancy to induce hyperhomocysteinemia, a model of developmental neurotoxicity, and pinealon was administered under these conditions. Offspring of treated dams showed significantly improved cognitive function, including better spatial orientation and learning ability, and their cerebellar neurons were more resistant to oxidative stress, with reduced reactive oxygen species accumulation and fewer necrotic cells in neuronal populations isolated from offspring cerebellum. The results confirmed in vivo the neuroprotective properties previously observed by the group in vitro.

### Penetration of Short Fluorescence-Labeled Peptides into the Nucleus in HeLa Cells and In Vitro Specific Interaction of the Peptides with Deoxyribooligonucleotides and DNA

Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF — *Biochemistry (Moscow)* (2011) — [PMID 22117547](https://pubmed.ncbi.nlm.nih.gov/22117547/) | [doi:10.1134/S0006297911110022](https://doi.org/10.1134/S0006297911110022)

This biophysical study established that ultrashort bioregulator peptides, including pinealon (Glu-Asp-Arg), epithalon, and testagen, can enter living cells: marked fluorescence appeared in the cytoplasm, nucleus, and nucleolus of HeLa cells after incubation with fluorescein-labeled peptides. Fluorescence-quenching assays with labeled deoxyribooligonucleotides and DNA-ethidium bromide complexes showed the peptides discriminate between nucleotide sequences and recognize cytosine methylation status; pinealon, like epithalon, bound preferentially to CAG-containing sequences. The authors propose that site-specific peptide-DNA interactions can epigenetically regulate gene activity, the foundational claim of the Khavinson bioregulator mechanism.

## Frequently Asked Questions

### What is Pinealon and how is it classified?

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (abbreviated EDR), developed in Vladimir Khavinson's bioregulator program in St. Petersburg. It belongs to the class of ultrashort peptides, compounds of 2 to 4 amino acids proposed to regulate gene expression by entering cells and interacting directly with DNA, rather than acting through cell-surface receptors. It is investigated primarily as a neuroprotective and geroprotective agent. Its formula (C15H26N6O8, 418.40 Da) and identity are registered in PubChem (CID 10273502).

### Has Pinealon been studied in Alzheimer's disease models?

Yes, in two complementary models. In an in vitro amyloid synaptotoxicity model, pinealon at 200 ng/ml increased mushroom dendritic spines in hippocampal neurons by 71 percent, restoring them to normal levels (PMID: 28853087). In 5xFAD transgenic Alzheimer's-model mice, pinealon and the related KED peptide prevented dendritic spine loss, with molecular docking identifying EDR binding sites in promoters of Alzheimer's-relevant genes including CASP3, APOE, SOD2, and PPARA/PPARG (PMID: 34071923). Both studies come from the same St. Petersburg research lineage and await independent replication.

### How does Pinealon interact with DNA?

Biophysical work showed that fluorescein-labeled pinealon penetrates HeLa cells and accumulates in the nucleus and nucleolus (PMID: 22117547). In vitro binding assays demonstrated that pinealon discriminates between nucleotide sequences, binding preferentially to CAG-containing oligonucleotides and responding to cytosine methylation status, which are features relevant to epigenetic regulation. Separate physical-chemistry studies characterized how mono- and divalent ions shape the Glu-Asp-Arg-DNA interaction (PMID: 30762356). This direct genome interaction is the proposed basis of its gene-expression effects.

### Has Pinealon been tested in humans?

No controlled human trials have been published. A Russian-language review (PMID: 24738258) describes clinical application of pinealon and other peptide neuroprotectors in elderly patients, and a mechanism review from the developing group states it improved memory issues in elderly patients, but these are uncontrolled observations from the originating research lineage rather than monitored trials. Human pharmacokinetics, effective dosing, and safety are uncharacterized by Western evidentiary standards.

### How does Pinealon differ from Semax or Cortexin?

Pinealon is a single defined tripeptide (Glu-Asp-Arg) proposed to act through direct DNA interaction and epigenetic gene regulation. Semax is a defined synthetic heptapeptide (an ACTH fragment analog) that acts mainly through BDNF upregulation and melanocortin and serotonergic systems. Cortexin is a complex mixture of brain-derived polypeptides. In a comparative aged-rat study (PMID: 28509493), Cortexin affected free-radical processes and caspase-3 activity more strongly than pinealon, while both promoted adrenergic mediator and serotonin accumulation under stress, indicating overlapping but non-identical pharmacology.

## Related Peptides

- [Semax](https://peptpedia.org/peptide/semax)
- [Cerebrolysin](https://peptpedia.org/peptide/cerebrolysin)
- [Epithalon](https://peptpedia.org/peptide/epithalon)
- [Cortagen](https://peptpedia.org/peptide/cortagen)

---

This content is for educational and research purposes only. It is not medical advice, and the compounds covered are research chemicals not approved for human use unless explicitly stated otherwise.

Cite this page: Peptpedia — Research Peptide Encyclopedia, https://peptpedia.org